Cardlytics, Inc.
US ˙ NasdaqGM ˙ US14161W1053

SecurityCDLX / Cardlytics, Inc.
InstitutionXTX Topco Ltd
Latest Disclosed Ownership36,552 shares
Latest Disclosed Value $ 38,380
XTX Topco Ltd reports 200.00% increase in ownership of CDLX / Cardlytics, Inc.

On May 15, 2026 - XTX Topco Ltd filed a 13F-HR form disclosing ownership of 36,552 shares of Cardlytics, Inc. (US:CDLX) valued at $38,380 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 12,184 shares of Cardlytics, Inc.. This represents a change in shares of 200.00% during the quarter. The current value of the position is $22,300 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CARDLYTICS COM 14161W105 36,552 24,368 200.00 38 171.43 0.0007
2026-02-17 2025-12-31 13F CARDLYTICS COM 14161W105 12,184 -18,112 -59.78 14 -80.82 0.0004
2025-11-14 2025-09-30 13F CARDLYTICS COM 14161W105 30,296 -55,675 -64.76 74 -48.23 0.0038
2025-08-12 2025-06-30 13F CARDLYTICS COM 14161W105 85,971 50,663 143.49 141 120.31 0.0059
2025-05-08 2025-03-31 13F CARDLYTICS COM 14161W105 35,308 -6,973 -16.49 64 -58.97 0.0033
2025-02-13 2024-12-31 13F CARDLYTICS COM 14161W105 42,281 42,281 157 0.0129
2024-11-14 2024-09-30 13F CARDLYTICS COM 14161W105 0 -12,978 -100.00 0 -100.00
2024-08-12 2024-06-30 13F CARDLYTICS COM 14161W105 12,978 12,978 107 0.0091
2023-11-13 2023-09-30 13F CARDLYTICS COM 14161W105 0 -22,283 -100.00 0 -100.00
2023-08-14 2023-06-30 13F CARDLYTICS COM 14161W105 22,283 22,283 141 0.0252
2023-05-12 2023-03-31 13F CARDLYTICS COM 14161W105 0 -26,704 -100.00 0 -100.00
2023-02-14 2022-12-31 13F CARDLYTICS COM 14161W105 26,704 11,184 72.06 154 5.48 0.0328
2022-11-14 2022-09-30 13F CARDLYTICS COM 14161W105 15,520 15,520 146 0.0361
2021-11-12 2021-09-30 13F CARDLYTICS COM 14161W105 0 -2,397 -100.00 0 -100.00
2021-08-12 2021-06-30 13F CARDLYTICS COM 14161W105 2,397 -2,696 -52.94 304 -45.62 0.1024
2021-05-14 2021-03-31 13F CARDLYTICS COM 14161W105 5,093 5,093 559 0.2716
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.